Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07856069) titled 'Arsenic Trioxide Combined With Chemotherapy for Relapsed SHH-Activated and/or TP53-Mutant Medulloblastoma' on Sept. 27.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Condition:
Medulloblastoma
Intervention:
Drug: Arsenic Trioxide (ATO)
Drug: ETOPOSIDE - Study
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: Methotrexate
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: October 2026
Target Sample Size:...